TRCT
XFOR icon

Tower Research Capital (TRC)’s X4 Pharmaceuticals XFOR Stock Holding History

Tower Research Capital (TRC)’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$743 Sell
180
-10,266
-98% -$38.5K ﹤0.01% 4790
2025
Q4 		$41.8K Sell
10,446
-233
-2% -$847 ﹤0.01% 2563
2025
Q3 		$36.5K Buy
10,679
+5,476
+105% +$14.1K ﹤0.01% 2768
2025
Q2 		$9.89K Buy
5,203
+4,185
+411% +$17.1K ﹤0.01% 3976
2025
Q1 		$7.22K Buy
1,018
+498
+96% +$6.86K ﹤0.01% 3970
2024
Q4 		$11.4K Buy
520
+161
+45% +$2.57K ﹤0.01% 3714
2024
Q3 		$7.21K Sell
359
-540
-60% -$11.3K ﹤0.01% 4067
2024
Q2 		$15.6K Buy
899
+359
+66% +$11.7K ﹤0.01% 3899
2024
Q1 		$22.5K Buy
540
+129
+31% +$3.59K ﹤0.01% 2892
2023
Q4 		$10.4K Buy
411
+68
+20% +$1.65K ﹤0.01% 4258
2023
Q3 		$11.2K Buy
343
+149
+77% +$6.5K ﹤0.01% 4024
2023
Q2 		$11.3K Buy
194
+167
+619% +$8.58K ﹤0.01% 3994
2023
Q1 		$1K Sell
27
-314
-92% -$9.21K ﹤0.01% 5632
2022
Q4 		$10K Buy
+341
New +$16.2K ﹤0.01% 4095
2022
Q3 		– Sell
-188
Closed -$5K – 6547
2022
Q2 		$5K Sell
188
-135
-42% -$5.13K ﹤0.01% 5116
2022
Q1 		$16K Buy
+323
New +$18.5K ﹤0.01% 3772
2021
Q4 		– Sell
-42
Closed -$7K – 6624
2021
Q3 		$7K Sell
42
-399
-90% -$65.6K ﹤0.01% 4683
2021
Q2 		$86K Buy
441
+340
+337% +$85.5K ﹤0.01% 2550
2021
Q1 		$26K Sell
101
-103
-50% -$27.1K ﹤0.01% 3690
2020
Q4 		$39K Sell
204
-382
-65% -$75K ﹤0.01% 3353
2020
Q3 		$119K Buy
586
+483
+469% +$116K ﹤0.01% 3017
2020
Q2 		$29K Buy
+103
New +$28.2K ﹤0.01% 3469
2019
Q3 		– Sell
-66
Closed -$30K – 4557
2019
Q2 		$30K Buy
66
+51
+340% +$25.9K ﹤0.01% 1918
2019
Q1 		$8K Buy
+15
New +$8.28K ﹤0.01% 2827
2018
Q4 		– Sell
-8
Closed -$3.05K – 4438
2018
Q3 		$2K Sell
8
-6
-43% -$2.54K ﹤0.01% 3492
2018
Q2 		$9K Buy
14
+3
+27% +$9.82K ﹤0.01% 2843
2018
Q1 		$44K Buy
+11
New +$32K ﹤0.01% 1745

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Tower Research Capital (TRC)'s XFOR Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its X4 Pharmaceuticals (XFOR) stake by 98% in Q1 2026, selling an estimated $38.5K and leaving 180 shares worth $743. The position accounts for ﹤0.01% of the portfolio, ranked #4790.

Tower Research Capital (TRC) first reported a position in XFOR in Q1 2018 and has held it in 27 quarters since. The position peaked at $119K in Q3 2020. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Tower Research Capital (TRC) held 180 shares of X4 Pharmaceuticals worth $743 as of Q1 2026.
  • Tower Research Capital (TRC) sold 10,266 X4 Pharmaceuticals shares in Q1 2026, an estimated $38.5K.
  • X4 Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4790 holding.
  • Tower Research Capital (TRC) first reported a position in X4 Pharmaceuticals in Q1 2018 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s X4 Pharmaceuticals position peaked at $119K in Q3 2020.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.